{
  "symbol": "NGNE",
  "company": "Neurogene Inc.",
  "generated_at": "2026-06-24T07:36:50.640Z",
  "event_count": 1,
  "events": [
    {
      "type": "scout_dossier",
      "ts": "2026-06-16T22:04:13.666Z",
      "summary": "Neurogene is a pre-revenue clinical-stage biotech focused on gene therapy for rare neurological diseases with its lead candidate NGN-401 in a registrational trial for Rett syndrome. The investigation triggered on a Form 4 cluster, but upon examination all three recent filings were SELLING transactions — Christine Mikail Cvijic's May 6 sales (9,600 shares via pre-set 10b5-1 plan) and Christina Shafer's option grant are not open-market purchases. The broader insider history shows mandatory tax-withholding sells on RSU vesting dates across multiple executives including CEO Rachel McMinn and CSO Stuart Cobb — none representing discretionary conviction buys. Dosing in the Embolden registrational trial was completed June 8, 2026, which is a genuine catalyst ahead of an August 11 earnings report. However, with no revenue, cash burn of ~$31M per quarter, analyst target at $80 vs. current price of $29.35 — this is not mispriced; the market appears correctly discounting binary biotech risk in an illiquid micro-cap with elevated IV (110-114%) and limited options liquidity.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 20,
      "walltime_min": 28,
      "debug_path": "dossiers/2026-06-16-NGNE.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "NGNE",
    "call": "BUY",
    "confidence": 5,
    "score": 7,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_strong_up": "+2 (60.5%)",
      "rsi_neutral": "0 (58.7)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (7d ago)",
      "from_high": "0 (-10.2%)"
    },
    "summary": "BUY (score +7) · 12-1 mom 60.5% · RSI 58.7 · above_both · -10.2% from high",
    "last_close": 30.86,
    "one_month_ago_close": 27.61,
    "twelve_month_ago_close": 17.2,
    "twelve_one_momentum_pct": 60.52,
    "rsi_14": 58.7,
    "ma_stack": "above_both",
    "from_period_high_pct": -10.21,
    "period_high": 34.37,
    "price_targets": {
      "bear": 23.26,
      "fair": 46.31,
      "bull": 180,
      "bear_return_pct": -24.6,
      "fair_return_pct": 50.1,
      "bull_return_pct": 483.3,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 46,
        "target_mean": 80,
        "target_high": 180,
        "analyst_count": 7
      }
    },
    "generated_at": "2026-06-24T07:36:50.637Z"
  }
}